Original-Research: Defence Therapeutics Inc. - von GBC AG

Einstufung von GBC AG zu Defence Therapeutics Inc.

Unternehmen: Defence Therapeutics Inc.
ISIN: CA24463V1013

Anlass der Studie: Research Report (Initial Coverage) Empfehlung: BUY
Kursziel: 11,02 CAD (7,06 EUR)
Kursziel auf Sicht von: 31.12.2022
Letzte Ratingänderung:
Analyst: Julien Desrosiers, Cosmin Filker

Uniquely Positioned with versatile ACCUM(TM); Enormous upside potential; Next generation of cancer treatment

- Proprietary platform technology with proven enhanced intracellular delivery. Promotes delivery of target product without non-specific protein/antigen degradation or interference.

- Strong versatility of the Accum(TM) platform. The company has published promising pre-clinical results in eleven different indications with various applications in ADCs, Cancer Vaccines, and ID Vaccines.

- Uniquely positioned. Accum(TM) technology is the next generation of cancer treatment.

- Massive upside potential. All their current research is pre-clinical and have shown remarkable results.

- Growth opportunity. The company is far from done unlocking the full potential of Accum(TM) technology.

- Attractive capital structure. The company has only 47.0M shares fully diluted

- Well financed. The company has currently enough cash on hand to complete their planned Phase I studies.

- Strong and Extensive experienced team in pre-clinical/clinical, business development, CMC and regulatory.

- Major milestones to be achieved within the next 6-12 months with many GLP ongoing studies and planned filing of Phase I studies for both Melanoma and breast cancer.

- Flexible business model: From royalties to JVs or full development. Accum(TM) technology allows for an optimized business model for each indication and possible near-term revenues.

- Based on our DCF model we have determine a price target of 11.02 CAD (7.60 EUR) per share and a BUY rating.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/23350.pdf

Kontakt für Rückfragen
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
++++++++++++++++
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,5b,6a,7,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date and time of completion of the study: 09/02/2022 (9:32 pm) Date and time of first transmission: 10/02/2022 (11:00 am)

-------------------übermittelt durch die EQS Group AG.-------------------

Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.